Frontier Biotechnologies 前沿生物
5 significant filings since 29 May 2026: 2 on regulatory inquiry, 2 on change of interest and 1 on major holder selling. The latest, on 13 Aug 2026: 前沿生物关于持股5%以上股东权益变动触及1%及5%刻度的提示性公告.
自 29 May 2026 起有 5 份重大公告：regulatory inquiry 2 份、change of interest 2 份、major holder selling 1 份。最新一份（13 Aug 2026）：前沿生物关于持股5%以上股东权益变动触及1%及5%刻度的提示性公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 开源证券 | 余汝意,巢舒然 | Buy 买入 | 2 Sep 2026 | 4 | — |
| 群益证券 | 王睿哲 | Outperform 增持 | 23 Jun 2026 | 1 | 22.00 |
Each row is a broker's latest report in the last twelve months. A price target is given in 1 of 5 reports. 每行为该券商近十二个月的最新研报；5 份中 1 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。